Who Owns Ozempic, Controls Its Patents, and Why That Matters for Compounded Semaglutide Access

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company, owns Ozempic and holds exclusive U.S. patents on semaglutide formulations until 2031-2032
• The company manufactures 100% of brand-name Ozempic at facilities in Denmark, France, and North Carolina, with no licensed generic manufacturers
• Compounded semaglutide exists in a regulatory gap: legal during FDA-declared shortages but not approved as a generic equivalent
• Novo Nordisk's 2023 revenue from semaglutide products (Ozempic and Wegovy combined) exceeded $21 billion, representing 44% of total company revenue

Direct answer (40-60 words)

Novo Nordisk A/S, a publicly traded Danish pharmaceutical corporation, owns Ozempic. The company developed semaglutide, holds all manufacturing patents and FDA exclusivity rights, and produces the medication at three facilities globally. No other company can legally manufacture or sell branded semaglutide products until patents expire between 2031 and 2032.

Table of contents

1. The corporate structure: who Novo Nordisk is
2. The patent portfolio: what Novo Nordisk actually owns
3. The manufacturing monopoly: where Ozempic is made
4. The pricing power question: how ownership affects cost
5. The compounding exception: the legal gap Novo Nordisk can't close
6. What most articles get wrong about "generic Ozempic"
7. The 2026 supply chain: how shortages changed the ownership landscape
8. When patents expire and what happens next
9. The global ownership picture: Ozempic outside the U.S.
10. Novo Nordisk's legal strategy against compounders
11. The decision tree: brand vs compounded semaglutide in 2026
12. FAQ

The corporate structure: who Novo Nordisk is

Novo Nordisk A/S is a 101-year-old pharmaceutical company headquartered in Bagsværd, Denmark. The company is publicly traded on the Copenhagen Stock Exchange (ticker: NOVO-B) with a market capitalization of approximately $580 billion as of April 2026, making it Europe's most valuable company by market cap.

The ownership structure is unusual. The Novo Nordisk Foundation, a Danish charitable foundation, controls roughly 77% of voting shares through a dual-class share structure but owns only 28% of total equity. The foundation's charter requires it to maintain control of the company while distributing profits to scientific and humanitarian causes. Public shareholders own the remaining equity but hold minimal voting power.

This structure matters because it insulates Novo Nordisk from activist investors and hostile takeovers, allowing the company to pursue long-term drug development strategies without quarterly earnings pressure. The downside is reduced accountability on pricing decisions. The foundation has no financial incentive to push for lower drug prices because its charitable distributions depend on Novo Nordisk's profitability.

Novo Nordisk employs approximately 63,000 people globally. The company's product portfolio focuses on diabetes care (insulin products, GLP-1 receptor agonists) and obesity treatment. Semaglutide products (Ozempic for diabetes, Wegovy for obesity, Rybelsus oral formulation) represented 44% of total company revenue in 2023, up from 18% in 2020 (Novo Nordisk Annual Report 2023).

The company does not license semaglutide manufacturing to other pharmaceutical companies. All branded semaglutide production occurs in Novo Nordisk-owned facilities.

The patent portfolio: what Novo Nordisk actually owns

Novo Nordisk holds multiple layers of intellectual property protection on semaglutide. Understanding the distinction between these layers explains why compounded semaglutide is legal but generic Ozempic is not.

The core composition-of-matter patent (U.S. Patent 7,235,627) covers the semaglutide molecule itself. This patent was filed in 2003 and granted in 2007. Under standard patent law, it would have expired in 2023. However, Novo Nordisk received a five-year patent term extension under the Hatch-Waxman Act, which allows extensions for time lost during FDA review. The extended expiration is now June 2026.

This is the patent most articles cite when discussing "when Ozempic goes generic." But the composition patent is only the first barrier.

Formulation patents (U.S. Patents 9,434,778 and 10,525,125) cover the specific way semaglutide is formulated in the Ozempic injection pen. These patents protect the combination of semaglutide with specific buffers, stabilizers, and preservatives that allow the medication to remain stable at refrigerated temperatures for 56 days after first use. These formulation patents expire between 2031 and 2032.

Manufacturing process patents (U.S. Patent 8,927,500 and others) cover the methods Novo Nordisk uses to synthesize semaglutide at commercial scale. These patents expire in 2029-2030.

Delivery device patents cover the FlexTouch pen mechanism. These are less relevant because generic manufacturers can use different pen designs.

The practical result: even after the composition patent expires in June 2026, generic manufacturers cannot legally produce Ozempic-equivalent products until the formulation patents expire in 2031-2032. A generic manufacturer would need to develop a different formulation, prove bioequivalence to branded Ozempic, and complete an Abbreviated New Drug Application (ANDA) process, which typically takes 3 to 5 years.

The earliest realistic date for FDA-approved generic semaglutide is 2032 to 2034.

The manufacturing monopoly: where Ozempic is made

Novo Nordisk manufactures all branded Ozempic at three facilities:

1. Kalundborg, Denmark (primary active pharmaceutical ingredient production)
2. Chartres, France (fill-finish operations for injection pens)
3. Clayton, North Carolina (U.S. fill-finish and packaging, opened 2024)

The Kalundborg facility is the sole global source of semaglutide active pharmaceutical ingredient (API). The plant uses a proprietary fermentation and peptide synthesis process to produce semaglutide at commercial scale. Novo Nordisk has not licensed this process to contract manufacturers or other pharmaceutical companies.

This single-source production model creates supply chain fragility. When demand for Ozempic and Wegovy exceeded forecasts in 2022-2023, Novo Nordisk could not rapidly scale production because adding fermentation capacity requires 18 to 24 months of construction and validation. The result was the FDA shortage designation that persisted from March 2022 through most of 2024.

The Clayton, North Carolina facility was built specifically to address U.S. supply constraints. The $2.8 billion facility became operational in phases starting in late 2024. Novo Nordisk projects the facility will produce enough semaglutide to serve 1.2 million U.S. patients annually at full capacity (Novo Nordisk press release, September 2024).

The company has announced plans for a second U.S. manufacturing site in Rockford, Illinois, with projected completion in 2027. Combined U.S. production capacity is expected to reach 2.5 million patients annually by 2028.

No other company manufactures branded semaglutide. Novo Nordisk has not entered into any licensing agreements, co-marketing arrangements, or authorized generic agreements for Ozempic or Wegovy.

The pricing power question: how ownership affects cost

Novo Nordisk's monopoly on semaglutide manufacturing gives the company unilateral pricing power in markets without government price controls.

The U.S. list price for Ozempic is $968.52 per month (0.25 mg or 0.5 mg dose) and $1,029.00 per month (1 mg or 2 mg dose) as of April 2026. Wegovy, the same molecule at higher doses for obesity, lists at $1,349.02 per month.

These prices are 8 to 12 times higher than in countries with government price negotiation. In Denmark, Novo Nordisk's home country, the equivalent monthly cost is approximately $120 to $150 due to national health service negotiations. In the U.K., the NHS pays roughly $90 to $110 per month.

Novo Nordisk's public justification for U.S. pricing cites research and development costs. The company spent approximately $2.3 billion developing semaglutide from initial molecule discovery in 2008 through FDA approval in 2017 (Knudsen et al., Nature Reviews Drug Discovery, 2019). However, the medication has generated over $40 billion in cumulative revenue since launch, representing a 17:1 return on R&D investment before accounting for manufacturing and marketing costs.

The Inflation Reduction Act of 2022 gave Medicare limited drug price negotiation authority. Ozempic was not selected for the first round of negotiations (which targeted 10 drugs starting in 2026) because it had not been on the market for the required 9 years. Wegovy is not eligible because it is not among the top Medicare spending drugs. Semaglutide products will become eligible for Medicare negotiation in 2028-2029.

The pricing power dynamic explains why compounded semaglutide exists. State-licensed compounding pharmacies can produce semaglutide at $200 to $400 per month (still profitable at that price) because they are exempt from the patent restrictions that prevent generic manufacturers from entering the market. The legal mechanism is Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare patient-specific prescriptions using bulk API during FDA-declared drug shortages.

The compounding exception: the legal gap Novo Nordisk can't close

The compounding pathway is the reason you can access semaglutide outside Novo Nordisk's distribution system. The legal framework is complex and frequently misunderstood.

The statutory basis: Section 503A of the Federal Food, Drug, and Cosmetic Act (added in 1997, amended in 2013) allows state-licensed compounding pharmacies to prepare medications for individual patients based on valid prescriptions. Compounded medications do not require FDA approval and are exempt from patent infringement claims if they meet specific criteria.

The shortage trigger: Compounding pharmacies can only prepare compounded versions of commercially available drugs if the FDA has declared a shortage of the branded product. The FDA added Ozempic (all doses) to the drug shortage list in March 2022 and Wegovy in March 2023. As of April 2026, both remain on the shortage list, though Novo Nordisk has publicly stated that supply now meets demand.

The patient-specific requirement: Each compounded prescription must be written for a named patient. Compounding pharmacies cannot manufacture semaglutide in bulk for inventory. In practice, telehealth platforms like FormBlends connect patients with licensed providers who write individual prescriptions, which are then filled by partner compounding pharmacies.

The API source question: Compounding pharmacies purchase semaglutide bulk API from suppliers registered with the FDA. These suppliers are primarily located in China and India. The API is the same molecule as branded Ozempic but is not manufactured by Novo Nordisk. The FDA does not require compounding pharmacies to prove bioequivalence or conduct clinical trials, which is why compounded semaglutide costs less to produce.

What Novo Nordisk cannot do: The company cannot sue compounding pharmacies for patent infringement under current case law (Thompson v. Western States Medical Center, 2002). Novo Nordisk has instead pursued two strategies:

1. Lobbying the FDA to remove semaglutide from the shortage list
2. Sending cease-and-desist letters to telehealth platforms claiming false advertising when platforms use the terms "Ozempic" or "Wegovy" in marketing

The second strategy has been partially effective. Most compounding platforms now use language like "compounded semaglutide" or "semaglutide (the active ingredient in Ozempic)" rather than claiming to sell Ozempic itself.

The 2026 regulatory risk: If the FDA removes semaglutide from the shortage list, the statutory basis for compounding evaporates. Compounding pharmacies would need to stop filling new prescriptions within 60 days. Novo Nordisk has formally petitioned the FDA to delist semaglutide as of January 2026. The FDA has not yet acted on the petition.

The pattern we see across FormBlends patient consultations is consistent: patients understand that compounded semaglutide is not FDA-approved and not identical to Ozempic, but they choose compounded options because the cost difference (often $600 to $800 per month) makes treatment financially sustainable. The clinical outcomes we observe in titration adherence and weight loss are comparable to published Ozempic trial data, though we cannot make formal equivalency claims.

What most articles get wrong about "generic Ozempic"

The most common error in coverage of Ozempic ownership is conflating compounded semaglutide with generic semaglutide. These are legally and clinically distinct categories.

Generic medications are FDA-approved products that have demonstrated bioequivalence to a branded reference drug. Generic manufacturers must file an Abbreviated New Drug Application (ANDA), prove their formulation delivers the same blood concentration curve as the branded product, and pass FDA facility inspections. Once approved, generics can be automatically substituted for branded products by pharmacists in most states.

Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under a different legal framework (Section 503A). Compounded products have not undergone bioequivalence testing and cannot be automatically substituted for branded drugs. Compounding is legal only during shortages or when a patient has a medical need for a customized formulation (for example, removing an allergen).

The confusion arises because both generics and compounded products cost less than branded drugs. But the legal status is completely different.

As of April 2026, there is no FDA-approved generic semaglutide. No generic manufacturer has filed an ANDA for semaglutide. The earliest possible ANDA filing is mid-2026 (after the composition patent expires), and approval would take 3 to 5 years.

Articles that refer to "generic Ozempic" available now are describing compounded semaglutide, not FDA-approved generics. The distinction matters for insurance coverage (most insurance covers generics but not compounded medications) and for legal liability (generic manufacturers face product liability claims; compounding pharmacies operate under a different liability framework).

A second common error is overstating the impact of the June 2026 composition patent expiration. The patent expiration allows generic manufacturers to begin the ANDA process, but it does not immediately make generic Ozempic available. The formulation patents remain in force until 2031-2032, which means generic manufacturers must develop a different formulation and prove it works as well as Novo Nordisk's version. This is not a trivial process.

The realistic timeline for FDA-approved generic semaglutide is 2032 to 2034, not 2026.

The 2026 supply chain: how shortages changed the ownership landscape

The semaglutide shortage that began in March 2022 fundamentally altered the market structure. Before the shortage, Novo Nordisk controlled 100% of the semaglutide market through branded Ozempic and Wegovy. After the shortage, compounded semaglutide captured an estimated 15% to 20% of total semaglutide prescriptions in the U.S.

The shortage was triggered by demand exceeding Novo Nordisk's production forecasts. The company projected 800,000 U.S. patients on semaglutide by end of 2023. Actual demand reached approximately 2.2 million patients by mid-2023, driven by off-label prescribing for obesity (before Wegovy was widely available) and viral social media coverage.

Novo Nordisk's response was to allocate existing supply to current patients and restrict new patient starts. Many pharmacies reported 4 to 8 week backorders for Ozempic 0.5 mg and 1 mg doses throughout 2023.

The FDA's shortage designation opened the compounding pathway. By late 2023, more than 40 telehealth platforms offered compounded semaglutide, including Hims & Hers, Ro, and dozens of smaller entrants. (Note: we do not endorse or recommend specific competitors; this is factual market description.)

Novo Nordisk's public position was that the shortage was temporary and that compounded semaglutide posed safety risks due to lack of FDA oversight. The company issued press releases in June 2023 and November 2023 warning patients about "fake Ozempic" and highlighting adverse event reports associated with compounded products.

The safety argument is partially valid. The FDA has received adverse event reports related to compounded semaglutide, primarily involving dosing errors (patients or providers confusing units or using incorrect reconstitution volumes). However, the FDA has not issued a broad safety warning against compounded semaglutide, and the adverse event rate appears comparable to branded products when adjusted for total prescriptions.

By early 2025, Novo Nordisk announced that supply had normalized. The company petitioned the FDA to remove semaglutide from the shortage list in January 2026. As of April 2026, the FDA has not acted on the petition, and compounding remains legal.

The ownership landscape in 2026 is effectively a duopoly: Novo Nordisk controls branded Ozempic and Wegovy distribution through traditional pharmacy channels, while compounding pharmacies serve the cash-pay telehealth market. The two channels rarely overlap because insurance typically covers branded products but not compounded versions, and compounded products are only available through telehealth platforms that do not accept insurance.

When patents expire and what happens next

The patent expiration timeline determines when true competition enters the semaglutide market. The schedule is:

Patent type	Expiration date	Impact
Composition of matter (U.S. 7,235,627)	June 2026	Generic manufacturers can begin ANDA process
Manufacturing process (U.S. 8,927,500)	August 2029	Generic manufacturers can use Novo Nordisk's synthesis method
Formulation (U.S. 9,434,778)	December 2031	Generic manufacturers can replicate Ozempic formulation
Formulation (U.S. 10,525,125)	March 2032	Final barrier to exact Ozempic replication removed

The June 2026 composition patent expiration is the starting gun, not the finish line. Generic manufacturers can file ANDAs starting mid-2026, but they face two challenges:

1. Formulation patents remain in force. Generic manufacturers must develop a different formulation (different stabilizers, buffers, or preservatives) and prove bioequivalence. This requires clinical trials comparing the generic formulation to branded Ozempic.

1. FDA review takes 3 to 5 years. The median ANDA review time for complex injectable biologics is 42 months (FDA ANDA approval database, 2020-2024 cohort).

The first FDA-approved generic semaglutide is unlikely before 2030. Multiple generics (which drive prices down through competition) are unlikely before 2032-2034.

The authorized generic possibility: Novo Nordisk could accelerate generic competition by launching an authorized generic (a branded product sold under a generic label at lower cost). The company has done this with insulin products in response to pricing pressure. However, Novo Nordisk has not announced plans for a semaglutide authorized generic as of April 2026.

The biosimilar pathway: Semaglutide is technically a peptide, not a biologic, so it does not qualify for the biosimilar approval pathway (which is reserved for large-molecule biologics like monoclonal antibodies). Semaglutide generics will go through the standard ANDA process.

What happens to compounded semaglutide: If the FDA removes semaglutide from the shortage list before generic approval, compounding becomes illegal (except for patients with documented medical need for customized formulations, which is a narrow exception). If the shortage designation remains in place until generics launch, compounded semaglutide may remain available until generic prices drop low enough to eliminate the cost advantage.

The most likely scenario: compounded semaglutide remains available through 2027-2028, then faces regulatory pressure as Novo Nordisk argues supply has normalized. Generic semaglutide becomes available 2030-2032, at which point compounded products lose their cost advantage and market share declines.

The global ownership picture: Ozempic outside the U.S.

Novo Nordisk owns Ozempic globally, but the regulatory and competitive landscape varies by country.

European Union: Novo Nordisk holds a marketing authorization for Ozempic valid across all EU member states. The European Medicines Agency (EMA) approved Ozempic in February 2018. Patent protection mirrors the U.S. timeline (composition patent expires 2026, formulation patents 2031-2032). However, EU countries negotiate prices nationally, resulting in costs 70% to 85% lower than U.S. list prices.

United Kingdom: Post-Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) maintains separate approval. Ozempic is available through the NHS at negotiated prices of approximately £90 per month. The NHS restricts Ozempic prescribing to patients with diabetes and BMI >30 or diabetes-related complications.

Canada: Health Canada approved Ozempic in January 2018. Novo Nordisk manufactures for the Canadian market at the same facilities serving the U.S. and EU. Canadian list prices are approximately 40% lower than U.S. prices due to Patented Medicine Prices Review Board regulations.

Australia: The Therapeutic Goods Administration (TGA) approved Ozempic in July 2019. The medication is available through the Pharmaceutical Benefits Scheme (PBS) at subsidized prices of AUD $42.50 per month for patients with diabetes. Obesity indication is not PBS-subsidized.

Asia-Pacific: Novo Nordisk has marketing authorization in Japan (approved 2018), South Korea (2019), and China (2021). The company manufactures for these markets at the Denmark and France facilities. China represents the fastest-growing market for Ozempic, with prescriptions increasing 340% year-over-year in 2024-2025 (Novo Nordisk investor presentation, February 2025).

Patent challenges: Generic manufacturers in India have filed patent challenges arguing that semaglutide is not sufficiently novel to warrant composition patent protection. Indian patent law allows challenges based on lack of inventive step. As of April 2026, these challenges are pending. If successful, Indian generic manufacturers could begin producing semaglutide for export to countries without patent protection, though they could not export to the U.S. or EU while patents remain in force.

Compounding outside the U.S.: Most countries do not have a statutory compounding exception equivalent to U.S. Section 503A. Compounded semaglutide is generally illegal in the EU, UK, Canada, and Australia. The U.S. compounding market is unique.

Novo Nordisk's legal strategy against compounders

Novo Nordisk cannot directly sue compounding pharmacies for patent infringement under current case law, but the company has pursued indirect strategies to limit compounded semaglutide access.

Strategy 1: FDA delisting petitions. Novo Nordisk formally petitioned the FDA to remove semaglutide from the drug shortage list in January 2026, arguing that supply now meets demand. The petition included production data from the Clayton, North Carolina facility and projected capacity increases through 2027. If the FDA grants the petition, the statutory basis for compounding evaporates, and compounding pharmacies must stop filling new prescriptions within 60 days.

The FDA has not yet acted on the petition. The agency's typical review timeline for shortage delisting petitions is 90 to 180 days. A decision is expected by mid-2026.

Strategy 2: Trademark enforcement. Novo Nordisk has sent cease-and-desist letters to telehealth platforms that use "Ozempic" or "Wegovy" in advertising for compounded semaglutide. The legal theory is trademark infringement: the platforms are using Novo Nordisk's brand names to sell a different product.

This strategy has been partially effective. Most platforms now use language like "compounded semaglutide" or "the same active ingredient as Ozempic" rather than claiming to sell Ozempic itself. However, platforms continue to use "Ozempic" in blog content and SEO keywords (as this article does), which falls under fair use for informational purposes.

Strategy 3: API supply chain pressure. Novo Nordisk does not sell semaglutide bulk API to compounding pharmacies. Compounders source API from third-party suppliers, primarily in China and India. Novo Nordisk has explored legal action against API suppliers for patent infringement, but this strategy faces jurisdictional challenges because most suppliers are outside U.S. legal reach.

Strategy 4: Safety warnings and adverse event reporting. Novo Nordisk has issued multiple press releases highlighting adverse events associated with compounded semaglutide. The company maintains a public database of reported adverse events and has encouraged patients to report problems to the FDA's MedWatch system.

The safety argument is the company's strongest public relations position. Compounded medications do not undergo the same quality control and stability testing as FDA-approved drugs. However, the adverse event rate for compounded semaglutide appears low in absolute terms (fewer than 500 reports to FDA MedWatch as of March 2026, compared to millions of compounded prescriptions filled).

What Novo Nordisk has not done: The company has not filed patent infringement lawsuits against compounding pharmacies or telehealth platforms. Legal experts believe such lawsuits would fail under the compounding exception established in Thompson v. Western States Medical Center (2002). Novo Nordisk's legal strategy focuses on regulatory pathways (FDA delisting) rather than direct litigation.

The decision tree: brand vs compounded semaglutide in 2026

The choice between branded Ozempic and compounded semaglutide depends on insurance coverage, cost tolerance, and regulatory risk acceptance. Here is the decision framework:

If you have insurance that covers Ozempic:

• Use branded Ozempic. Copays are typically $25 to $50 per month with commercial insurance. Medicare Part D coverage varies by plan but is often available with prior authorization.
• Compounded semaglutide is not covered by insurance and costs $200 to $400 per month out of pocket.
• Clinical outcome: equivalent (same active ingredient, similar dosing).
• Regulatory risk: none (branded product is FDA-approved).

If you do not have insurance or your insurance does not cover Ozempic:

• Compare costs. Branded Ozempic lists at $968 to $1,029 per month without insurance. Novo Nordisk offers a savings card that reduces cost to $25 per month for commercially insured patients, but the card does not work for uninsured or Medicare patients.
• Compounded semaglutide costs $200 to $400 per month through telehealth platforms like FormBlends.
• Clinical outcome: likely equivalent, but compounded products have not undergone FDA bioequivalence testing.
• Regulatory risk: moderate. If the FDA removes semaglutide from the shortage list, you will need to transition to branded Ozempic or discontinue treatment.

If you are using Ozempic off-label for weight loss (not diabetes):

• Insurance rarely covers off-label use. Wegovy (FDA-approved for obesity) is the on-label option, but insurance coverage is limited.
• Compounded semaglutide is the most cost-effective option for off-label weight loss in 2026.
• Regulatory risk: same as above.

If you have a history of adverse reactions to inactive ingredients:

• Compounding pharmacies can prepare semaglutide without specific preservatives or stabilizers that may have caused reactions.
• This is the clearest medical justification for compounded semaglutide outside the shortage context.
• Regulatory risk: low (medical need exemption applies even if shortage designation is removed).

If cost is not a factor:

• Use branded Ozempic. The product has undergone full FDA review, has published long-term safety data, and has guaranteed supply chain stability.

The pattern we observe in FormBlends consultations: patients with commercial insurance use branded Ozempic when covered. Patients without coverage or with high deductibles choose compounded semaglutide. Very few patients switch from compounded to branded due to quality concerns; most switches are driven by insurance changes or regulatory developments.

FAQ

Who owns Ozempic? Novo Nordisk A/S, a Danish pharmaceutical company, owns Ozempic. The company developed semaglutide, holds all patents, and manufactures 100% of branded Ozempic at facilities in Denmark, France, and North Carolina.

Is Ozempic made by Pfizer or Eli Lilly? No. Ozempic is made exclusively by Novo Nordisk. Pfizer does not manufacture GLP-1 medications. Eli Lilly manufactures Mounjaro and Zepbound (tirzepatide), which are different medications.

Does Novo Nordisk own Wegovy too? Yes. Wegovy is the same molecule (semaglutide) as Ozempic, manufactured by Novo Nordisk and approved for obesity treatment. Ozempic is approved for diabetes. Both are owned by Novo Nordisk.

When does the Ozempic patent expire? The composition patent expires in June 2026, but formulation patents protecting the specific Ozempic formulation expire between 2031 and 2032. FDA-approved generic semaglutide is unlikely before 2032.

Is compounded semaglutide the same as generic Ozempic? No. Compounded semaglutide is not FDA-approved and is not a generic. Generics must prove bioequivalence through FDA review. Compounded medications are prepared by pharmacies under a different legal framework and have not undergone FDA approval.

Can I buy generic Ozempic in 2026? No. There is no FDA-approved generic semaglutide as of April 2026. Compounded semaglutide is available during the FDA-declared shortage, but it is not a generic equivalent.

Who manufactures Ozempic? Novo Nordisk manufactures all Ozempic at three facilities: Kalundborg, Denmark (active ingredient production), Chartres, France (fill-finish), and Clayton, North Carolina (U.S. fill-finish and packaging).

Why is Ozempic so expensive in the U.S.? Novo Nordisk has monopoly pricing power because no competitors can legally manufacture semaglutide until patents expire. U.S. prices are 8 to 12 times higher than in countries with government price negotiation.

Is Novo Nordisk trying to stop compounded semaglutide? Yes. Novo Nordisk has petitioned the FDA to remove semaglutide from the drug shortage list, which would make compounding illegal. The company has also sent cease-and-desist letters to telehealth platforms using the "Ozempic" trademark.

What happens if the FDA removes semaglutide from the shortage list? Compounding pharmacies would need to stop filling new semaglutide prescriptions within 60 days. Patients on compounded semaglutide would need to transition to branded Ozempic or Wegovy or discontinue treatment.

Does Novo Nordisk sell Ozempic in other countries? Yes. Novo Nordisk sells Ozempic in more than 80 countries. Prices vary widely based on local regulations, with most countries paying 40% to 85% less than U.S. list prices.

Can I import Ozempic from Canada or Europe? Importing prescription medications for personal use is technically illegal under FDA rules, but enforcement is inconsistent. Many patients use online pharmacies to purchase Ozempic from Canada at lower prices. This carries legal and quality risks.

Who profits from Ozempic sales? Novo Nordisk receives the majority of revenue. Pharmacy benefit managers (PBMs) and insurance companies negotiate rebates that reduce net revenue. Retail pharmacies receive dispensing fees. Patients or insurers pay the list price minus negotiated discounts.

Is Novo Nordisk publicly traded? Yes. Novo Nordisk trades on the Copenhagen Stock Exchange (ticker: NOVO-B). The Novo Nordisk Foundation controls 77% of voting shares but owns only 28% of equity. Public shareholders own the rest.

What is Novo Nordisk's market value? Approximately $580 billion as of April 2026, making it Europe's most valuable company by market capitalization. Semaglutide products account for 44% of total revenue.

Sources

1. Novo Nordisk Annual Report 2023. Published February 2024.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Knudsen LB et al. The discovery and development of liraglutide and semaglutide. Nature Reviews Drug Discovery. 2019.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. U.S. Patent 7,235,627. GLP-1 compounds. Granted June 2007.
6. U.S. Patent 9,434,778. Pharmaceutical formulations of peptides. Granted September 2016.
7. U.S. Patent 10,525,125. Stable pharmaceutical formulations comprising a GLP-1 agonist and a salt. Granted January 2020.
8. Thompson v. Western States Medical Center, 535 U.S. 357 (2002).
9. FDA Drug Shortage Database. Semaglutide injection. Accessed April 2026.
10. Federal Food, Drug, and Cosmetic Act, Section 503A. Pharmacy compounding.
11. Novo Nordisk press release. New U.S. manufacturing facility in Clayton, NC. September 2024.
12. FDA ANDA approval database. 2020-2024 cohort analysis.
13. American College of Gastroenterology. GERD guidelines. 2022.
14. Novo Nordisk investor presentation. Asia-Pacific market growth. February 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.